Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27

被引:43
|
作者
Montgomery, HE
Kiernan, LA
Whitworth, CE
Fleming, S
Unger, T
Gohlke, P
Mullins, JJ
McEwan, JR
机构
[1] UCL, Sch Med, Hatter Inst Cardiovasc Studies, London W1N 8AA, England
[2] Univ Edinburgh, Ctr Genome Res, Edinburgh, Midlothian, Scotland
[3] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland
[4] Univ Kiel, Inst Pharmacol, Kiel, Germany
关键词
renin-angiotensin system; malignant hypertension; transgenic rats;
D O I
10.1097/00004872-199816050-00011
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Activation of the renin-angiotensin system has been implicated strongly in the transition from benign to malignant hypertension. However, the concomitant rise in blood pressure might also have a direct effect on the vascular wall by initiating fibrinoid necrosis and myointimal proliferation, Ascertaining the relative importance of these two factors in this process has proved difficult. TGR(mREN2)27 heterozygotes (HanRen2/Edin--) have previously been shown to develop malignant hypertension spontaneously and exhibit the characteristic features of human malignant hypertension, Objective Tissue renin-angtiotensin systems have been implicated in the pathogenesis of malignant hypertension, We set out to determine whether inhibition of this system might protect against development of the disease in a rat model, Method Male TGR(mREN2)27 heterozygotes (n = 24) were given a non-hypotensive dose of the angiotensin converting enzyme inhibitor ramipril (5 mu g/kg per day) from 28 to 120 days of age, untreated rats acting as controls (n = 40), The incidences of malignant hypertension were compared. Systolic blood pressure was measured by tail-cuff plethysmography during treatment; tissue and plasma angiotensin converting enzyme levels and renal histological changes were assessed at the end of the treatment period or upon development of malignant hypertension. Results Sixty-three per cent of control rats and 4% of angiotensin converting enzyme inhibitor-treated rats had developed malignant hypertension by 120 days despite there having been no significant difference in systolic blood pressure throughout the course of treatment. Angiotensin converting enzyme activities in kidney, heart and resistance vessels, though not that in plasma, were significantly lower in the treated rats, The degree of medial wall thickening did not differ between the two groups whereas evidence of tissue injury (e.g. intimal fibrosis, fibrinoid necrosis and nephron injury) was significantly less common among rats in the angiotensin converting enzyme inhibitor-treated group, Conclusions Tissue angiotensin converting enzyme inhibition at a non-hypotensive dose almost completely prevented mortality from malignant hypertension and significantly reduced tissue injury in this model, implicating angiotensin II rather than high blood pressure as the principal 'vasculotoxic' agent in malignant hypertension, (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:635 / 643
页数:9
相关论文
共 50 条
  • [41] Signal transduction in cardiac and vascular tissue from normotensive and transgenic hypertensive TGR(mREN2)27 rats
    Witte, K
    Schnecko, A
    Perbandt, K
    Höfer, S
    Lemmer, B
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 341 (2-3) : 337 - 341
  • [42] ENHANCED ALDOSTERONE BIOSYNTHESIS IN TGR(MREN2)27 - FUNCTIONAL-SIGNIFICANCE OF AN INTRAADRENAL RENIN-ANGIOTENSIN SYSTEM
    PETERS, J
    DJAVIDANI, B
    MUNTER, K
    BADER, M
    SANDER, M
    MULLINS, J
    GANTEN, D
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1992, 21 (11) : 545 - 546
  • [43] Comparison between chronic converting enzyme inhibition and AT(1) blockade in mRen2 transgenic rats
    Lantelme, P
    Lo, M
    Mullins, JJ
    Gharib, C
    Bizollon, CA
    Sassard, J
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (04) : 476 - 481
  • [44] Metabolic and cardiovascular adjustments to hemorrhage in [TGR(ASrAogen)] rats and (mRen2)27 rats
    de Lima, Daniel C.
    Shaltout, Hossam A.
    Coimbra, Candido Celso
    Diz, Debra I.
    FASEB JOURNAL, 2012, 26
  • [45] THE ROLE OF THE ADRENAL-GLAND IN HYPERTENSIVE TRANSGENIC RAT TGR(MREN2)27
    SANDER, M
    BADER, M
    DJAVIDANI, B
    MASERGLUTH, C
    VECSEL, P
    MULLINS, J
    GANTEN, D
    PETERS, J
    ENDOCRINOLOGY, 1992, 131 (02) : 807 - 814
  • [46] Functional evidence of cardiovascular pathophysiology in the TGR(mRen2)27 transgenic rat.
    Gelband, CH
    Pachori, A
    Kochera, R
    Numan, MT
    Byrne, BJ
    Katovich, MJ
    Ganten, D
    Ferrario, CM
    Raizada, MK
    FASEB JOURNAL, 1999, 13 (04): : A342 - A342
  • [47] From genotype to phenotype - Behavior of the transgenic rat TGR(mRen2)27 as an example
    Voigt, JP
    Rex, A
    Bader, M
    Fink, H
    REVIEWS IN THE NEUROSCIENCES, 2000, 11 (01) : 37 - 45
  • [48] PRESSURE-NATRIURESIS RESPONSE (PNR) IN HYPERTENSIVE TGR (MREN2)27 RATS
    SPRINGATE, JE
    VANLIEW, JB
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 551 - 551
  • [49] Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats
    Veniant, M
    Whitworth, CE
    Menard, J
    Sharp, MGF
    Gonzales, MF
    Bruneval, P
    Mullins, JJ
    AMERICAN JOURNAL OF HYPERTENSION, 1995, 8 (12) : 1167 - 1176
  • [50] ANGIOTENSIN AND BRADYKININ PEPTIDES IN THE TGR(MREN-2)27 RAT
    CAMPBELL, DJ
    RONG, P
    KLADIS, A
    REES, B
    GANTEN, D
    SKINNER, SL
    HYPERTENSION, 1995, 25 (05) : 1014 - 1020